5 Ways Israel Is Changing The Pharmaceutical Industry, One Drug At A Time.

Nearly 7 out of 10 Americans are on Prescription drugs. Prescription drug use has increased steadily in the U.S. for the past decade. Check out 5 ways Israel has contributed to advancing the pharmaceutical industry and the treatment of various medical conditions and disease states.

1. FDA Approved Teva Generic Drugs for Breast Cancer and Depression

israelvalley.s3-eu-west-1.amazonaws.com

Israeli generic pharmaceuticals giant, Teva Pharmaceutical Industries, has received US Food and Drug Administration (FDA) approval for generic versions of two new drugs – the breast cancer drug Arimidex, made by AstraZeneca, and the antidepressant, Effexor XR, by Wyeth.

2. FDA Approved Copaxone Used for Treatment of Multiple Sclerosis (MS)

haaretz.com!/image/2833724698.jpg_gen

The FDA has approved an expanded indication for the drug Copaxone, developed by Israel’s Teva Pharmaceutical Industries, to include the treatment of patients from the very earliest stage of MS. It has been demonstrated that early treatment initiation delays the severity of symptoms.

3. FDA Approved Azilect for Treatment of Parkinson’s Disease

image.ec21.com

Teva Pharmaceutical’s Azilect received the seal of approval by the FDA to treat Parkinson’s Disease (PD) in June of 2014. Studies have shown it to be effective as monotherapy in early PD, and a useful adjunct to dopamine agonist therapy in moderate-to-advanced PD.

4. MAPI Pharma Drugs for MS and Schizophrenia in Clinical Trial phases II & I in the US

multiplesclerosisnewstoday.com

Once-a-month treatment for MS, and the painkiller Tapentadol, gain US patents – inching the Israeli pharma company closer to the market. These drugs are predicted to be approved within the next two years.

5. Immune Pharmaceuticals’ Drugs Use Antibodies to Effectively Target Inflammatory Diseases and Cancer

cfhu.org

A new drug delivery system puts thousands of toxic pharmaceutical molecules inside a targeted missile which goes off only when it reaches diseased tissues. Israeli product Bertilimumab, used for inflammatory diseases, is Immune Pharmaceutical’s leading product undergoing phase II clinical trials currently.